O
Olivier Mir
Researcher at Paris Descartes University
Publications - 152
Citations - 4087
Olivier Mir is an academic researcher from Paris Descartes University. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 32, co-authored 128 publications receiving 3581 citations. Previous affiliations of Olivier Mir include Institut Gustave Roussy & Curie Institute.
Papers
More filters
Journal ArticleDOI
Sarcopenia Predicts Early Dose-Limiting Toxicities and Pharmacokinetics of Sorafenib in Patients with Hepatocellular Carcinoma
Olivier Mir,Romain Coriat,Benoit Blanchet,Jean-Philippe Durand,Pascaline Boudou-Rouquette,Judith Michels,Stanislas Ropert,Michel Vidal,Stanislas Pol,Stanislas Chaussade,François Goldwasser +10 more
TL;DR: Among cirrhotic Child Pugh A patients with advanced HCC, sarcopenia predicts sorafenib exposure and the occurrence of DLT within the first month of treatment.
Journal ArticleDOI
Breast cancer in pregnancy: Recommendations of an international consensus meeting
Frédéric Amant,Sarah Deckers,Kristel Van Calsteren,Sibylle Loibl,Michael J. Halaska,Lieselot Brepoels,Jos H. Beijnen,Fatima Cardoso,Oreste Gentilini,Lieven Lagae,Olivier Mir,Patrick Neven,Nelleke Ottevanger,Steven Pans,Fedro A. Peccatori,Roman Rouzier,Hans-Jörg Senn,Henk Struikmans,Marie Rose Christiaens,David Cameron,Andreas du Bois +20 more
TL;DR: The treatment of breast cancer in pregnancy should be executed by experienced specialists in a multidisciplinary setting and should adhere as closely as possible to standard protocols.
Journal ArticleDOI
Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients
Olivier Huillard,Olivier Mir,M. Peyromaure,Camille Tlemsani,Julie Giroux,Pascaline Boudou-Rouquette,Stanislas Ropert,N. Barry Delongchamps,Marc Zerbib,François Goldwasser +9 more
TL;DR: Patients with sarcopenia and a BMI<25 kg m−2 experienced significantly more DLTs during the first cycle of treatment, which is a significant predictor of toxicity in metastatic renal cell cancer patients treated with sunitinib.
Journal ArticleDOI
Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial
Jean-Philippe Durand,Gael Deplanque,Vincent Montheil,J.M. Gornet,Florian Scotté,Olivier Mir,Anatole Cessot,Romain Coriat,Eric Raymond,Emmanuel Mitry,P. Herait,Y. Yataghene,François Goldwasser +12 more
TL;DR: Venlafaxine has clinical activity against oxaliplatin-induced acute neurosensory toxicity and the primary end point was the percentage of patients with a 100% relief under treatment.
Journal ArticleDOI
Sorafenib-Induced Hepatocellular Carcinoma Cell Death Depends on Reactive Oxygen Species Production In Vitro and In Vivo
Romain Coriat,Carole Nicco,Christiane Chéreau,Olivier Mir,Jérôme Alexandre,Stanislas Ropert,Bernard Weill,Stanislas Chaussade,François Goldwasser,Frédéric Batteux +9 more
TL;DR: Sorafenib dose-dependently induces the generation of ROS in tumor cells in vitro and in vivo and can be used as a marker of effectiveness of the drug.